Drug
L.M.X4
L.M.X4 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_3
1
33%
Ph not_applicable
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn1
Terminated1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
withdrawn133%
terminated133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_3
Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
NCT00187135
withdrawnnot_applicable
Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing
NCT01842373
completedphase_4
LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery
NCT00847093
Clinical Trials (3)
Showing 3 of 3 trials
NCT00187135Phase 3
Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
NCT01842373Not Applicable
Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing
NCT00847093Phase 4
LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3